Bonus Biogroup Ltd (BONS)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	n/a
Revenue (ttm)	n/a
Net Income (ttm)	-7.62M
Shares Out	n/a
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About BONS

Bonus Biogroup is a clinical-stage biotechnology company focused on developing next-generation therapies. Our mission is to develop and deliver safe, effective, and affordable tissue engineering and cell therapy products that address severe conditions with limited treatment options. We are developing BonoFill, a personalized, autologous tissue-engineered live-human bone graft, and MesenCure, an enhanced allogeneic cell therapy for inflammation and tissue damage, both of which, we believe, may address significant unmet clinical and market needs.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1981
• Employees: 49
• Stock Exchange: NASDAQ
• Ticker Symbol: BONS
• Website: https://www.bonus-bio.com/

Financial Performance

Financial numbers in ILS